Compare STRA & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | ADMA |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 1996 | 2012 |
| Metric | STRA | ADMA |
|---|---|---|
| Price | $76.41 | $8.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $87.00 | $25.67 |
| AVG Volume (30 Days) | 261.1K | ★ 3.3M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ 15.85 | N/A |
| EPS | ★ 1.48 | 0.19 |
| Revenue | ★ $997,137,000.00 | $42,219,783.00 |
| Revenue This Year | $4.71 | $27.46 |
| Revenue Next Year | $4.67 | $22.11 |
| P/E Ratio | $52.03 | ★ $45.92 |
| Revenue Growth | ★ 57.23 | 43.85 |
| 52 Week Low | $69.70 | $7.21 |
| 52 Week High | $87.38 | $20.46 |
| Indicator | STRA | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 42.87 | 45.80 |
| Support Level | $72.13 | $8.23 |
| Resistance Level | $84.55 | $8.97 |
| Average True Range (ATR) | 2.67 | 0.26 |
| MACD | -0.59 | -0.03 |
| Stochastic Oscillator | 21.84 | 30.29 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.